Company Profile

Imclone Systems Inc
Profile last edited on: 12/21/22      CAGE:       UEI:

Business Identifier: Biologic medicines in the area of oncology
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

908 541 8100 440 Route 22
East Bridgewater, NJ 08807
   (908) 541-8100
Location: Single
Congr. District: 07
County: Somerset

Public Profile

In October 2008, beating out an earlier bid by Bristol-Myers Squibb, Imclone Systems Inc was acquired by Eli Lilly, and is now operating as a wholly-owned subsidiary of the larger firm. Imclone Systems is a biopharmaceutical company that is primarily engaged in the research and development of drugs and other products for the treatment of cancer and cancer-related disorders. The Company has three cancer-related products that are being developed, two of which are being tested in clinical trials. The Products are C225 Cancer Therapeutic, BEC2 Cancer Vaccine, and c-p1C11 Monoclonal Antibody Inhibitor of Angiogenesis. The Company also conducts research programs on developing inhibitors of tyrosine kinase receptors, a research on antibodies that inhibit vascular-specific cadherin (VE-cadherin) and researches on possible cancer vaccines. In addition, the Company has developed the technology necessary to isolate endothelial stem cells and is also conducting a research in hematopoiesis.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2000 1 NIH $99,000
Project Title: Active Tumor Immunotherapy Targeting the VEGF Receptor
1997 1 NIH $99,087
Project Title: Ve-Cadherin--A Novel Target for Inhibiting Angiogenesis
1987 1 NIH $50,000
Project Title: Rapid detection for HTLV-III

Key People / Management

  Daniel Lynch -- CEO

  Harlan W Waksal -- Founder, President and CEO

  Nicholas Giorgio

  Daniel J Hicklin

  Yiwen Li

  Samuel D Waksal